Gene therapy for diabetic retinopathy in animal models and humans

3Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Gene therapy is considered as one of the innovative treatment modalities for diabetic retinopathy (DR). Since genuine animal models of DR are limited, only a few studies have reported the efficacy of gene therapy. For preclinical study of DR, spontaneously diabetic Torii (SDT) rat is a valuable model. Fortunately, we could evaluate the efficacy of adeno-associated virus (AAV)-mediated gene therapy in SDT rats and proved that sFlt-1 expression prevented DR progression. Because of a limited number of large-animal models of DR, it is uncertain whether gene therapy experiments using dogs or monkeys allow reliable conclusions. On the other hand, owing to the recent progress in AAV-mediated gene therapy for retinal diseases in monkeys and humans, gene therapy for DR using AAV vectors may become a reality in the near future. © Mizukami et al.

Cite

CITATION STYLE

APA

Mizukami, H., Urabe, M., Kume, A., & Ozawa, K. (2011). Gene therapy for diabetic retinopathy in animal models and humans. Open Diabetes Journal, 4(SPEC. ISSUE 1), 119–122. https://doi.org/10.2174/1876524601104010119

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free